ClinicalTrials.gg

Program

HLX109

A development code.

Its studies are led by Fosun Pharma.

Furthest: phase 1, since Oct 18, 20261 company-led study, 1 open or runningNext primary completion: Sep 20, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since Oct 18, 2026Oct 18, 2026Sep 20, 2027phase 1 · NCT07935941

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2026First study: phase 1 study in First in Man Study to Evaluate Initial SafetyFirst studyNCT07935941 · 64 planned · Australia, China

Ahead

  1. Sep 20, 2027Primary completion: phase 1 study in First in Man Study to Evaluate Initial SafetyNCT07935941

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07935941First in Man Study to Evaluate Initial Safety · Australia, China1Not yet recruitingSep 20, 202764

How it is read

Names in the registry

  • “HLX109”, 7 entries

Codes read as this program: HLX109.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.